Home » Topics » Regulatory » EMA

EMA
RSS

AbbVie's Humira receives positive opinion from EMA for uveitis

July 24, 2017

EMA committee backs approval of Janssen's Symtuza

July 24, 2017

EMA's CHMP grants positive opinion for dupixent for the treatment of atopic dermatitis

July 24, 2017

EMA committee recommends approval of label update for Lixiana

July 17, 2017

EMA validates pacritinib MAA for patients with myelofibrosis who have thrombocytopenia

July 14, 2017

Gilead Sciences' MAA for bictegravir/emtricitabine/tenofovir alafenamide FDC validated by EMA

July 14, 2017

ProQR Therapeutics receives orphan drug designations in E.U. and U.S. for QRX-411

July 7, 2017

RDD Pharma's RDD-0315 given orphan drug status in E.U.

July 7, 2017

Polatuzumab vedotin is eligible for access to EMA's PRIME program

June 30, 2017

Global Blood Therapeutics' GBT-440 obtains EMA PRIME designation

June 29, 2017

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 21, 2026
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...